Evidence map›Paper›PMID 33050329›Full record

ReviewInternational journal of molecular sciences2020

Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors.

Jana de Sostoa, Valérie Dutoit, Denis Migliorini

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jana de SostoaBrain Tumor and Immune Cell Engineering Laboratory, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.ORCID 0000-0001-8563-9273
Valérie DutoitBrain Tumor and Immune Cell Engineering Laboratory, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.ORCID 0000-0002-3469-4237
Denis MiglioriniBrain Tumor and Immune Cell Engineering Laboratory, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.
University of Geneva · CH

Funding

ISREC Cancer Research Foundation ME11647Swiss Bridge Foundation ME11711
6 · The paper itself

Abstract

Malignant brain tumors remain incurable diseases. Although much effort has been devoted to improving patient outcome, multiple factors such as the high tumor heterogeneity, the strong tumor-induced immunosuppressive microenvironment, and the low mutational burden make the treatment of these tumors especially challenging. Thus, novel therapeutic strategies are urgent. Oncolytic viruses (OVs) are biotherapeutics that have been selected or engineered to infect and selectively kill cancer cells. Increasingly, preclinical and clinical studies demonstrate the ability of OVs to recruit T cells and induce durable immune responses against both virus and tumor, transforming a "cold" tumor microenvironment into a "hot" environment. Besides promising clinical results as a monotherapy, OVs can be powerfully combined with other cancer therapies, helping to overcome critical barriers through the creation of synergistic effects in the fight against brain cancer. Although many questions remain to be answered to fully exploit the therapeutic potential of OVs, oncolytic virotherapy will clearly be part of future treatments for patients with malignant brain tumors.

Indexed as

Genetic TherapyOncolytic VirotherapyAnimalsBiomarkers, TumorBrain NeoplasmsClinical Trials as TopicCombined Modality TherapyDrug Evaluation, PreclinicalGenetic VectorsGene Transfer TechniquesHumansOncolytic VirusesTransduction, GeneticTreatment OutcomeBiomarkers, Tumorcancer immunotherapyclinical trialscombination therapymalignant brain tumorsoncolytic viruses

Identifiers

PMID33050329
PMCPMC7589928
OpenAlexW3092382424

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.